Galderma Korea
This sponsor has funded 2 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 17600 | Ongoing | Safety and efficacy evaluation of Mirvaso gel 0.33 % (brimonidine tartrate) by Post marketing surveillance | No | No |
| 22329 | Planned | Post marketing surveillance to evaluate Soolantra cream 1% for the treatment of inflammatory lesions of rosacea in adult patients | No | No |
PAS by Risk Management Plan (RMP) requirement
Galderma Korea
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Galderma Korea
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Galderma Korea
1 Study countries specified are the following:
- Korea, Republic of